Super Session 5 - Rare Diseases - Development trends and strategies of orphan drugs
Wednesday, September 9, 2015
•
S15
•
4:45 PM
>
5:45 PM
•
Super Session 5 - Rare Diseases - Development trends and strategies of orphan drugs
•
Plenary Room A2
Session hosted by Sanofi & co-hosted by Voisin Consulting Life Sciences
Rare diseases are recognized as an important public health issue and a challenge to medical care. In recent years, much progress has been made with the initiation of regulatory frameworks, and an increase in orphan drug designations has been observed. The session will include exchanges of views on different stages of development of orphan drugs, including regulatory aspects, development trends and strategies, experience from investing in orphan drug companies, and the industry perspective on market access.
Moderator: Dr. Frédéric Pailloux, Head Senior Director Drugs and Biologics, Voisin Consulting Life Sciences
Speakers:
Dr. Olaf Ritzeler, R&D Partnerships Director, Strategy, Science Policy & External Innovation, Sanofi
Mr. Marten Steen, Partner, HealthCap
Ms. Wills Hughes-Wilson, Senior Vice President, Chief Patient Access Officer, Sobi
|